Gyre Therapeutics Inc. (GYRE) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Gyre Therapeutics Inc. (NASDAQ: GYRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.56 (-28.94% 1D, market cap $714.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GYRE ranks #341 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GYRE carries a Roarable D (47/100 RQD), trailing P/E of 72.3x, gross margin of 95.4%, and ROIC of 25.4%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and APMD (Apnimed Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per GYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124105), Gyre Therapeutics Inc. generated $116.6M in revenue (+10.2% YoY), $9.9M in net income, and -$180.0K in free cash flow against $219.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 95.4% Gross Margin
Altman Z-Score 14.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Macro rate sensitivity & RSI-14 (49.8) create a -15 pt regime headwind
While GYRE currently carries a cautious 47/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.72) and Max Pain ($4.79) forces dealer call-delta covering toward $9.60.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Gyre Therapeutics Inc. (GYRE) dropped -28.94% to $4.56, trading at 2% of its 52-week range ($4.52 – $9.14). Stretched risk/reward at 72x P/E (25% return on capital) under elevated 10-year interest-rate pressure.
TradingView report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036126040506/ef20080299_8k.htm
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GYRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GYRE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Gyre Therapeutics Inc. (GYRE) ranks #341 by composite RQD confidence (47/100, grade D) and #398 by equity capitalization ($714.8M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. GYRE currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GYRE
ACTIVE
Gyre Therapeutics Inc. | D | 47/100 | 72.3x | 95.4% | 25.4% | -28.94% | $714.8M | Benchmark Subject |
| WVE Wave Life Sciences Inc. | E | 22/100 | — | — | -35.0% | -1.10% | $715.9M | /wve-vs-gyre → |
| APMD Apnimed Inc. | D | 44/100 | — | — | — | -5.42% | $721.9M | /apmd-vs-gyre → |
| SGMT Sagimet Biosciences Inc. (Series A) | D | 45/100 | — | — | -35.0% | -4.89% | $735.7M | /sgmt-vs-gyre → |
| DSGN Design Therapeutics Inc. | D- | 35/100 | — | — | -32.1% | -3.44% | $692.2M | /dsgn-vs-gyre → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gyre Therapeutics Inc. (GYRE) reported GAAP revenue of $116.6M (+10.2% vs. FY2024 revenue of $105.8M , and +2.8% cumulative change since FY2023) , GAAP net income of $9.9M, operating cash flow of $1.0M, and free cash flow of -$180.0K (+97.0% YoY). On the balance sheet, GYRE closed FY2025 with $219.8M in total assets against $0 in total debt (Altman Z-Score: 14.33, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $116.6M | $9.9M | $1.0M | -$180.0K | $219.8M | — |
| FY2024 (FY) | 2024-12-31 | $105.8M | $17.9M | -$3.6M | -$6.0M | $125.4M | — |
| FY2023 (FY) | 2023-12-31 | $113.5M | -$85.5M | $25.9M | $25.9M | — | — |
As of 2026-11-02, Gyre Therapeutics Inc. (NASDAQ: GYRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.56 (-28.94% 1D, market cap $714.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GYRE ranks #341 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GYRE carries a Roarable D (47/100 RQD), trailing P/E of 72.3x, gross margin of 95.4%, and ROIC of 25.4%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and APMD (Apnimed Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per GYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124105), Gyre Therapeutics Inc. generated $116.6M in revenue (+10.2% YoY), $9.9M in net income, and -$180.0K in free cash flow against $219.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
GYRE last traded at $4.56 (-28.94% on volume of 394,091 shares), positioning the stock -32.14% below its 50-day simple moving average ($6.72) and -34.67% below its 200-day simple moving average ($6.98). Across its 52-week range of $4.52 to $9.14, GYRE sits at the 0.9% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.99 to $5.13).
Why GYRE Stock dropped -28.94% Today — RQD Quant Desk Flash. Stretched risk/reward at 72x P/E (25% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, GYRE carries an RQD Score of 47 and a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars:
For a prospective investor, the rating reads as a warning rather than an endorsement. The strongest pillar (fundamentals) is undercut by negative FCF yield and a 72.3 trailing P/E, while the signal pillars (whale flow, insider conviction, macro fit) all score in the lower range. The valuation tradeoff is that the market is pricing substantial future earnings growth relative to the trailing EPS of 0.09. Upside would require sustained earnings expansion and cash conversion; the rating itself flags distribution risk rather than accumulation.
Gyre Therapeutics Inc. (GYRE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it carries a market capitalization of $0.7B. Source data does not detail specific products, customer segments, or revenue model beyond reported financial results.
Per the butterfly supply-chain graph, supply_chain is NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Gyre Therapeutics Inc. (GYRE) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Gyre Therapeutics Inc. (GYRE) market action, institutional positioning, and fundamental catalysts.
Welcome to the GYRE (Gyre Therapeutics Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (25.4% ROIC), while bears focus on valuation multiple compression (72.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on GYRE, but look at what you are paying: 72.3x trailing P/E with 95.4% gross margins. Unless Gyre Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on GYRE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.41 (52-wk range $4.52 - $9.14), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).